Seagen Inc SGEN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/22 EDT
146.55quote price arrow up+146.55 (UNCH)
Volume
83,470
Close
146.55quote price arrow up+4.01 (+2.81%)
Volume
929,222
52 week range
105.43 - 192.79
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close146.55
  • 52 Week High192.79
  • 52 Week High Date11/08/21
  • 52 Week Low105.43
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap26.977B
  • Shares Out184.08M
  • 10 Day Average Volume1.55M
  • Dividend-
  • Dividend Yield-
  • Beta0.82
  • YTD % Change-5.21

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close146.55
  • 52 Week High192.79
  • 52 Week High Date11/08/21
  • 52 Week Low105.43
  • 52 Week Low Date05/09/22
  • Market Cap26.977B
  • Shares Out184.08M
  • 10 Day Average Volume1.55M
  • Dividend-
  • Dividend Yield-
  • Beta0.82
  • YTD % Change-5.21

RATIOS/PROFITABILITY

  • EPS (TTM)-3.77
  • P/E (TTM)-38.83
  • Fwd P/E (NTM)-38.42
  • EBITDA (TTM)-624.906M
  • ROE (TTM)-21.47%
  • Revenue (TTM)1.669B
  • Gross Margin (TTM)79.92%
  • Net Margin (TTM)-41.32%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date07/27/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Seagen Inc

There is no recent news for this security.

Profile

MORE
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib...
Roger Dansey M.D.
Interim Chief Executive Officer
Todd Simpson
Chief Financial Officer
Vaughn Himes Ph.D.
Chief Technical Officer
Chip Romp
Executive Vice President - Commercial U.S.
Lee Heeson
Executive Vice President - Commercial International
Address
21823 30Th Drive Se, Suite
Bothell, WA
98021
United States

Top Peers

SYMBOLLASTCHG%CHG
RPRX
Royalty Pharma PLC
41.36+1.10+2.73%
HZNP
Horizon Therapeutics PLC
92.90+2.08+2.29%
BMRN
Biomarin Pharmaceutical Inc
79.12+1.80+2.33%
CTLT
Catalent Inc
100.76+3.09+3.16%
UTHR
United Therapeutics Corp
190.99+5.86+3.17%